Detailed Information on Publication Record
2020
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study
HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ et. al.Basic information
Original name
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study
Authors
HORŇÁK, Tomáš (703 Slovakia, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Zuzana ŠUSTKOVÁ (203 Czech Republic, belonging to the institution), Jiřina PROCHÁZKOVÁ (203 Czech Republic), Petra BELOHLAVKOVA (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Peter ROHON (203 Czech Republic), Edgar FABER (203 Czech Republic), Pavel ZAK (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution)
Edition
LEUKEMIA & LYMPHOMA, LONDON, TAYLOR & FRANCIS, 2020, 1042-8194
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.280
RIV identification code
RIV/00216224:14110/20:00115331
Organization unit
Faculty of Medicine
UT WoS
000489439400001
Keywords in English
serum lipids; cardiovascular risk; nilotinib and imatinib therapy
Tags
International impact, Reviewed
Změněno: 28/1/2021 14:12, Mgr. Tereza Miškechová
Abstract
V originále
Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.
Links
LM2018128, research and development project |
| ||
NV17-30397A, research and development project |
|